JP2016538344A5 - - Google Patents

Download PDF

Info

Publication number
JP2016538344A5
JP2016538344A5 JP2016554555A JP2016554555A JP2016538344A5 JP 2016538344 A5 JP2016538344 A5 JP 2016538344A5 JP 2016554555 A JP2016554555 A JP 2016554555A JP 2016554555 A JP2016554555 A JP 2016554555A JP 2016538344 A5 JP2016538344 A5 JP 2016538344A5
Authority
JP
Japan
Prior art keywords
cancer
composition
administered
different
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016554555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538344A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/066436 external-priority patent/WO2015077354A1/en
Publication of JP2016538344A publication Critical patent/JP2016538344A/ja
Publication of JP2016538344A5 publication Critical patent/JP2016538344A5/ja
Pending legal-status Critical Current

Links

JP2016554555A 2013-11-19 2014-11-19 癌処置としてのstingアゴニストの使用 Pending JP2016538344A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906330P 2013-11-19 2013-11-19
US61/906,330 2013-11-19
PCT/US2014/066436 WO2015077354A1 (en) 2013-11-19 2014-11-19 Use of sting agonist as cancer treatment

Publications (2)

Publication Number Publication Date
JP2016538344A JP2016538344A (ja) 2016-12-08
JP2016538344A5 true JP2016538344A5 (ko) 2018-02-01

Family

ID=53180098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554555A Pending JP2016538344A (ja) 2013-11-19 2014-11-19 癌処置としてのstingアゴニストの使用

Country Status (4)

Country Link
US (2) US20160287623A1 (ko)
EP (1) EP3071209A4 (ko)
JP (1) JP2016538344A (ko)
WO (1) WO2015077354A1 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル-マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
JP7209697B2 (ja) 2017-08-31 2023-01-20 ブリストル-マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2624873B1 (en) 2010-10-06 2019-12-04 President and Fellows of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
LT2838515T (lt) 2012-04-16 2020-03-10 President And Fellows Of Harvard College Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
EP2943565B1 (en) 2013-01-14 2018-03-28 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
SG10201708821RA (en) 2013-04-29 2017-12-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
AP2015008700A0 (en) 2013-05-18 2015-08-31 Univ California Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
EP3027227A4 (en) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
JP6462006B2 (ja) 2014-06-04 2019-01-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingのモジュレーターとしての環式ジヌクレオチド
CN107148424B (zh) 2014-12-16 2021-01-08 凯拉治疗股份公司 用于诱导细胞因子的环状二核苷酸
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
AU2016259020B2 (en) 2015-05-07 2021-12-09 Baylor College Of Medicine Dendritic cell immunotherapy
WO2017011444A1 (en) * 2015-07-13 2017-01-19 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating b cell cancers
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
AU2016304899B2 (en) 2015-08-13 2018-11-08 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
WO2017062838A1 (en) 2015-10-07 2017-04-13 Nant Holdings Ip, Llc Activation of immune-related signalling pathways in cells via optofection
BR112018008339A2 (pt) 2015-10-28 2018-10-30 Aduro Biotech Inc composições e métodos para ativar estimulador de sinalização dependente do gene de interferon
AU2016362697B2 (en) * 2015-12-03 2018-07-12 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of STING
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
BR112018013808A2 (pt) 2016-01-11 2018-12-11 Innate Tumor Immunity, Inc. dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer
WO2017123675A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
DK3506884T3 (da) 2016-08-30 2021-07-26 Dana Farber Cancer Inst Inc Sammensætninger til indgivelse af medicin og anvendelser af disse
WO2018045204A1 (en) 2016-08-31 2018-03-08 Ifm Therapeutics, Inc Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
AR109788A1 (es) * 2016-10-04 2019-01-23 Merck Sharp & Dohme Compuestos de benzo[b]tiofeno como agonistas de sting
WO2018065360A1 (de) 2016-10-07 2018-04-12 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
RU2019122598A (ru) * 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
EP4371584A2 (en) * 2016-12-21 2024-05-22 Fred Hutchinson Cancer Center Scaffolds to treat solid tumor cells and escape variants
CN110913875A (zh) * 2017-01-06 2020-03-24 同生运营公司 程序化以在肿瘤细胞中产生免疫调节子和抗癌治疗剂的微生物
AU2018212788A1 (en) * 2017-01-27 2019-07-25 Janssen Biotech, Inc. Cyclic dinucleotides as STING agonists
ES2891326T3 (es) 2017-01-27 2022-01-27 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de la STING
CA3051252A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
JP2018131427A (ja) * 2017-02-17 2018-08-23 国立研究開発法人理化学研究所 免疫細胞の制御技術
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2018189382A1 (en) 2017-04-14 2018-10-18 Solstice Biologics, Ltd. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
WO2018232217A1 (en) 2017-06-16 2018-12-20 William Marsh Rice University Hydrogel delivery of sting immunotherapy for treatment of cancer
EP3431484A1 (en) * 2017-07-21 2019-01-23 Ludwig-Maximilians-Universität München A fluorescent cyclic dinucleotide and its use in methods of identifying substances having an ability to modulate the cgas/sting pathway
EP3661498A4 (en) * 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
US11312772B2 (en) 2017-08-04 2022-04-26 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
WO2019046511A1 (en) * 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
JP7262451B2 (ja) * 2017-10-05 2023-04-21 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Stingアゴニストの投与方法
CN111566119A (zh) 2017-11-10 2020-08-21 武田药品工业有限公司 Sting调节剂化合物以及制备和使用方法
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
WO2019134707A1 (zh) * 2018-01-08 2019-07-11 成都先导药物开发股份有限公司 一种免疫调节剂
EP4242212A3 (en) 2018-03-23 2023-11-15 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
CA3093849A1 (en) 2018-03-23 2019-09-26 Codiak Biosciences, Inc. Extracellular vesicles comprising sting-agonist
TWI793294B (zh) * 2018-04-03 2023-02-21 美商默沙東有限責任公司 Sting促效劑化合物
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP2021525706A (ja) 2018-05-25 2021-09-27 インサイト・コーポレイションIncyte Corporation Sting活性化剤としての三環式複素環式化合物
JP7335277B2 (ja) * 2018-06-01 2023-08-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 膀胱がんの治療のための方法
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
CN112041325B (zh) 2018-08-16 2023-10-24 卫材R&D管理有限公司 化合物的盐及其晶体
MA53438A (fr) 2018-08-24 2021-09-15 Codiak Biosciences Inc Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées
WO2020049534A1 (en) * 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
WO2020057546A1 (zh) * 2018-09-21 2020-03-26 上海迪诺医药科技有限公司 环状二核苷酸类似物、其药物组合物及应用
US11161864B2 (en) 2018-10-29 2021-11-02 Venenum Biodesign, LLC Sting agonists
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
EP3891165A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
US20220033435A1 (en) * 2018-12-07 2022-02-03 Merck Sharp & Dohme Corp. Cyclic Di-Nucleotide Compounds as STING Agonists
EP3891164A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
US20220125821A1 (en) * 2019-01-10 2022-04-28 Nankai University Cyclic dinucleotide prodrug molecule, preparation method therefor and application thereof
AU2020231115A1 (en) 2019-03-07 2021-08-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
CA3133314A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
WO2020191361A2 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
EP3994158A1 (en) 2019-07-03 2022-05-11 Codiak BioSciences, Inc. Extracellular vesicles targeting t cells and uses thereof
US20220259254A1 (en) 2019-07-05 2022-08-18 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
TW202114710A (zh) * 2019-07-25 2021-04-16 英屬開曼群島商百濟神州有限公司 作為sting促效劑之環狀二核苷酸
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021062290A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
JP2022549328A (ja) 2019-09-25 2022-11-24 コディアック バイオサイエンシーズ, インコーポレイテッド 細胞外小胞組成物
US20230241089A1 (en) 2019-09-25 2023-08-03 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
JP2022551420A (ja) 2019-09-25 2022-12-09 コディアック バイオサイエンシーズ, インコーポレイテッド 腫瘍を治療するためのil-12提示エクソソームとstingアゴニスト含有エクソソームとの併用
US20240165144A1 (en) * 2019-10-16 2024-05-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating innate immune signaling pathways
CN115427458A (zh) 2020-02-28 2022-12-02 塔拉克治疗公司 转谷氨酰胺酶介导的缀合
US20230114434A1 (en) 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ, インコーポレイテッド 治療のための細胞外小胞
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
CN115835856A (zh) 2020-05-13 2023-03-21 麻省理工学院 聚合物微装置的组合物以及其在癌症免疫疗法中的用途
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
EP4192506A1 (en) 2020-08-07 2023-06-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
CA3192470A1 (en) 2020-09-23 2022-03-31 Tim SOOS Methods of producing extracellular vesicles
US20230390409A1 (en) 2020-10-30 2023-12-07 Avacta Life Sciences Limited Fap-activated serum extended half-life therapeutic conjugates
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
EP4046634A1 (en) * 2021-02-17 2022-08-24 Centre national de la recherche scientifique Serca2 modulators and their therapeutic uses
CA3215049A1 (en) 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
WO2022223619A1 (en) 2021-04-20 2022-10-27 Institut Curie Compositions and methods for use in immunotherapy
WO2022223622A1 (en) 2021-04-20 2022-10-27 Institut Curie Compositions and methods for use in immunotherapy
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Cd70結合劑、其結合物及其使用方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
DE60128969T2 (de) * 2000-04-05 2007-10-18 Fujifilm Corp. Magnetbandkassette
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US6994349B2 (en) * 2002-03-08 2006-02-07 Action Target, Inc. Portable dueling tree
GB0517387D0 (en) * 2005-08-26 2005-10-05 Antisoma Res Ltd Combinations for the treatment of cancer
WO2010017248A2 (en) * 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
AU2013358892B2 (en) * 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
AP2015008700A0 (en) * 2013-05-18 2015-08-31 Univ California Compositions and methods for activating "stimulator of interferon gene"-dependent signalling

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル-マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
JP7209697B2 (ja) 2017-08-31 2023-01-20 ブリストル-マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド

Similar Documents

Publication Publication Date Title
JP2016538344A5 (ko)
JP2019501204A5 (ko)
JP2016501221A5 (ko)
WO2016161410A3 (en) Treatment of cancer using inhibitors of tgf-beta and pd-1
CN106687454B8 (zh) 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途
JP2016514689A5 (ko)
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
EA201690608A1 (ru) Способы лечения раковых заболеваний
JP2015512398A5 (ko)
MD20160016A2 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
NZ726365A (en) Combinations for treating cancers
WO2016080810A3 (ko) 바이구아나이드 화합물 및 이의 용도
WO2012103457A3 (en) Stilbene analogs and methods of treating cancer
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.
EP3453714A3 (en) Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
WO2017027359A8 (en) Pyridines and their use in the treatment of cancer
MX2017012068A (es) Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos.
UA113413C2 (uk) Пептид mphosph1 та вакцина, що його містить
JP2019506382A5 (ko)
WO2014011713A3 (en) Anti-proliferative compounds and uses thereof
JP2017516827A5 (ko)
JP2016523961A5 (ko)
EA201590909A1 (ru) Соединения триазолона и их применение